Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
University of Maryland, Baltimore
750 participants
Mar 31, 2025
OBSERVATIONAL
Conditions
Summary
The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
Eligibility
Inclusion Criteria4
- years old or older
- Patient at University of Maryland Baltimore Washington Medical Center
- Willing and able to consent to study procedures listed in the protocol
- Ability to speak and understand English
Exclusion Criteria4
- Younger than 18 years old
- Patient not cared for at University of Maryland Baltimore Washington Medical Center
- Unable to consent to study procedures listed in the protocol
- Unable to speak or understand English
Interventions
Up to 15 ml of blood will be collected from each patient at various time points throughout their 5 years of participation. DNA extraction, bisulfite conversion and analysis of epigenetic markers through PCR or next-generation sequencing will be performed. An epigenetic signature assay will then be identified.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07008664